Wegovy vs. Victoza
See how Wegovy and Victoza compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Wegovy (semaglutide) is FDA-approved for chronic weight management and cardiovascular risk reduction in adults with obesity, while Victoza (liraglutide) treats type 2 diabetes and its related cardiovascular risk.
Both drugs share a boxed warning for thyroid C-cell tumors and cause similar gastrointestinal side effects like nausea and diarrhea.
Wegovy is injected once a week at a higher maximum dose, while Victoza requires a daily injection at a lower maximum dose.
Wegovy vs. Victoza Drug Summary
Wegovy
Wegovy is a GLP-1 receptor agonist given as a once-weekly injection. It is FDA-approved for chronic weight management in adults and adolescents with obesity or overweight, and to lower cardiovascular risk in adults with heart disease and obesity. It is not approved for treating diabetes.
Victoza
Victoza is a GLP-1 receptor agonist given as a once-daily injection. It is FDA-approved to improve blood sugar control in adults and children with type 2 diabetes, and to lower cardiovascular risk in adults with diabetes and heart disease. It is not approved for weight management.
Wegovy vs. Victoza Side Effects
Wegovy
Victoza
Wegovy vs. Victoza Dosage
Wegovy
Victoza
| STAGE | DOSE | WHEN |
| Starting dose | 0.25 mg once weekly | Weeks 1-4 |
| Maximum dose | 2.4 mg once weekly | Week 17 onward |
| Dose changes | 4 increases | Every 4 weeks |
| STAGE | DOSE | WHEN |
| Starting dose | 0.6 mg once daily | Week 1 |
| Maximum dose | 1.8 mg once daily | Week 3 onward |
| Dose changes | 2 increases | Every week |
Wegovy
| STAGE | DOSE | WHEN |
| Starting dose | 0.25 mg once weekly | Weeks 1-4 |
| Maximum dose | 2.4 mg once weekly | Week 17 onward |
| Dose changes | 4 increases | Every 4 weeks |
Victoza
| STAGE | DOSE | WHEN |
| Starting dose | 0.6 mg once daily | Week 1 |
| Maximum dose | 1.8 mg once daily | Week 3 onward |
| Dose changes | 2 increases | Every week |
Wegovy vs. Victoza Indications
Wegovy
Wegovy is prescribed for long-term weight management alongside diet and exercise in people with obesity or a weight-related condition like high blood pressure. It also carries an indication to reduce the risk of heart attack, stroke, and cardiovascular death in adults with obesity and existing heart disease.
Chronic weight management in adults with obesity or overweight plus a related condition
Approved for adolescents 12 and older
Reduces risk of major cardiovascular events in adults with established heart disease
Used alongside diet and exercise
Victoza
Victoza is prescribed to improve blood sugar control in adults and children 10 and older with type 2 diabetes, used alongside diet and exercise. It also carries an indication to reduce the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and existing heart disease.
Glycemic control in adults and children 10 and older with type 2 diabetes
Reduces risk of major cardiovascular events in adults with type 2 diabetes and heart disease
Used alongside diet and exercise
Not approved for weight management
Wegovy vs. Victoza Pros and Cons
Wegovy
Wegovy's higher maintenance dose and weight-specific approval make it the more established option for chronic weight management, backed by cardiovascular outcomes data in people without diabetes. Insurance coverage for weight loss indications can still be inconsistent.
Pros
FDA-approved specifically for weight management, not just off-label use
Only needs one injection per week
Approved for adolescents as young as 12
Cons
Newer to market with less long-term real-world data than Victoza
Longer titration schedule before reaching maintenance dose
Not approved for treating type 2 diabetes
Victoza
Victoza has over a decade of real-world use for type 2 diabetes and a well-established safety record, including pediatric data. Its once-daily injection and lower maximum dose can mean smaller weight loss results if used off-label for that purpose.
Pros
Longer track record, on the market since 2010
Approved for children as young as 10 with type 2 diabetes
Simple three-step dose titration completed within weeks
Cons
Requires a daily injection instead of a once-weekly one
Not FDA-approved for weight management
Generally produces less weight loss than Wegovy at approved doses
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.